Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Discontinued OperationsCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mimedx Group (MDXG) Capital Expenditures: 2011-2025

Historic Capital Expenditures for Mimedx Group (MDXG) over the last 15 years, with Sep 2025 value amounting to $192,000.

  • Mimedx Group's Capital Expenditures rose 12.28% to $192,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.0 million, marking a year-over-year decrease of 45.26%. This contributed to the annual value of $1.7 million for FY2024, which is 15.30% down from last year.
  • Mimedx Group's Capital Expenditures amounted to $192,000 in Q3 2025, which was up 7.26% from $179,000 recorded in Q2 2025.
  • In the past 5 years, Mimedx Group's Capital Expenditures ranged from a high of $1.9 million in Q1 2021 and a low of $105,000 during Q2 2024.
  • For the 3-year period, Mimedx Group's Capital Expenditures averaged around $401,636, with its median value being $299,000 (2023).
  • Its Capital Expenditures has fluctuated over the past 5 years, first plummeted by 93.92% in 2022, then surged by 436.44% in 2023.
  • Over the past 5 years, Mimedx Group's Capital Expenditures (Quarterly) stood at $325,000 in 2021, then soared by 105.23% to $667,000 in 2022, then slumped by 35.98% to $427,000 in 2023, then crashed by 38.41% to $263,000 in 2024, then grew by 12.28% to $192,000 in 2025.
  • Its last three reported values are $192,000 in Q3 2025, $179,000 for Q2 2025, and $377,000 during Q1 2025.